Literature DB >> 34140643

LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing.

Yang-Hsiang Lin1,2, Meng-Han Wu2, Yi-Chung Liu3, Ping-Chiang Lyu4, Chau-Ting Yeh5, Kwang-Huei Lin6,7,8,9.   

Abstract

Long non-coding RNAs (lncRNA) play crucial roles in hepatocellular carcinoma (HCC) progression. However, the specific functions of lncRNAs in alternative splicing (AS) and the metastatic cascade in liver cancer remain largely unclear. In this study, we identified a novel lncRNA, LINC01348, which was significantly downregulated in HCC and correlated with survival functions in HCC patients. Ectopic expression of LINC01348 induced marked inhibition of cell growth, and metastasis in vitro and in vivo. Conversely, these phenotypes were reversed upon knockdown of LINC01348. Mechanistically, LINC01348 complexed with splicing factor 3b subunit 3 (SF3B3) acted as a modulator of EZH2 pre-mRNA AS, and induced alterations in JNK/c-Jun activity and expression of Snail. Notably, C-terminal truncated HBx (Ct-HBx) negatively regulated LINC01348 through c-Jun signaling. Our data collectively highlight those novel regulatory associations involving LINC01348/SF3B3/EZH2/JNK/c-Jun/Snail are an important determinant of metastasis in HCC cells and support the potential utility of targeting LINC01348 as a therapeutic strategy for HCC.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34140643     DOI: 10.1038/s41388-021-01905-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  Eliminating hepatitis B virus through neonatal vaccination: can we make it?

Authors:  Chau-Ting Yeh; Ming-Wei Lai
Journal:  J Hepatol       Date:  2012-06-07       Impact factor: 25.083

2.  Site-finding of Leucochloridiomorpha constantiae (Trematoda) metacercariae to the bursa of Fabricius of the domestic chick.

Authors:  B Fried; J D Bradford
Journal:  J Parasitol       Date:  1984-04       Impact factor: 1.276

3.  C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma.

Authors:  Karen M F Sze; Glanice K Y Chu; Joyce M F Lee; Irene O L Ng
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

4.  Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Authors:  Joong-Won Park; Yoon Jun Kim; Do Young Kim; Si-Hyun Bae; Seung Woon Paik; Youn-Jae Lee; Hwi Young Kim; Han Chu Lee; Sang Young Han; Jae Youn Cheong; Oh Sang Kwon; Jong Eun Yeon; Bo Hyun Kim; Jaeseok Hwang
Journal:  J Hepatol       Date:  2018-12-06       Impact factor: 25.083

5.  A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.

Authors:  F Donato; P Boffetta; M Puoti
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

6.  C-terminal-truncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis.

Authors:  Ivan Quetier; Nicolas Brezillon; Julien Revaud; James Ahodantin; Lucie DaSilva; Patrick Soussan; Dina Kremsdorf
Journal:  J Gen Virol       Date:  2014-12-17       Impact factor: 3.891

7.  Prevalence of Chronic Hepatitis B Virus Infection in the United States.

Authors:  Joseph K Lim; Mindie H Nguyen; W Ray Kim; Robert Gish; Ponni Perumalswami; Ira M Jacobson
Journal:  Am J Gastroenterol       Date:  2020-06-01       Impact factor: 10.864

Review 8.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

9.  A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.

Authors:  J Shi; L Zhu; S Liu; W-F Xie
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

10.  Hepatocellular Carcinoma: a Comprehensive Review ofzzm321990Biomarkers, Clinical Aspects, and Therapy

Authors:  Nathalia Martines Tunissiolli; Márcia Maria Urbanin Castanhole-Nunes; Patrícia Matos Biselli-Chicote; Érika Cristina Pavarino; Renato Ferreira da Silva; Rita de Cássia Martins Alves da Silva; Eny Maria Goloni-Bertollo
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01
View more
  4 in total

1.  CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer.

Authors:  Hsiang-Wei Huang; Ching-Ying Chen; Ya-Hui Huang; Chau-Ting Yeh; Chia-Siu Wang; Cheng-Chih Chang; Kwang-Huei Lin
Journal:  Oncogene       Date:  2021-10-29       Impact factor: 9.867

Review 2.  RNA splicing: a dual-edged sword for hepatocellular carcinoma.

Authors:  Anjali Kashyap; Greesham Tripathi; Avantika Tripathi; Rashmi Rao; Manju Kashyap; Anjali Bhat; Deepak Kumar; Anjali Rajhans; Pravindra Kumar; Darshan Shimoga Chandrashekar; Riaz Mahmood; Amjad Husain; Hatem Zayed; Alok Chandra Bharti; Manoj Kumar Kashyap
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 3.  Long non-coding RNAs are involved in alternative splicing and promote cancer progression.

Authors:  Jiawei Ouyang; Yu Zhong; Yijie Zhang; Liting Yang; Pan Wu; Xiangchan Hou; Fang Xiong; Xiayu Li; Shanshan Zhang; Zhaojian Gong; Yi He; Yanyan Tang; Wenling Zhang; Bo Xiang; Ming Zhou; Jian Ma; Yong Li; Guiyuan Li; Zhaoyang Zeng; Can Guo; Wei Xiong
Journal:  Br J Cancer       Date:  2021-11-08       Impact factor: 9.075

4.  LPAL2 Suppresses Tumor Growth and Metastasis of Hepatocellular Carcinoma by Modulating MMP9 Expression.

Authors:  Yang-Hsiang Lin; Yu-Chin Liu; Cheng-Yi Chen; Hsiang-Cheng Chi; Meng-Han Wu; Po-Shuan Huang; Cheng-Chih Chang; Tzu-Kang Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.